ArticleMolecular therapy. Nucleic acids2021
TSMDA: Target and symptom-based computational model for miRNA-disease-association prediction.
Article in Molecular therapy. Nucleic acids, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Machine learning for extracellular vesicles enables diagnostic and therapeutic nanobiotechnology.Journal of nanobiotechnology · 2026Review
- Mitigating sub-synchronous oscillation using intelligent damping control of DFIG based on improved TD3 algorithm with knowledge fusion.Scientific reports · 2024Article
- Advances in applications of artificial intelligence algorithms for cancer-related miRNA research.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024Review
- MicroRNAs: Small but Key Players in Viral Infections and Immune Responses to Viral Pathogens.Biology · 2023Review
- LEGO-CSM: a tool for functional characterization of proteins.Bioinformatics (Oxford, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The emergence of high-throughput sequencing techniques has revealed a primary role of microRNAs (miRNAs) in a wide range of diseases, including cancers and neurodegenerative disorders. Understanding novel relationships between miRNAs and diseases can potentially unveil complex pathogenesis mechanisms, leading to effective diagnosis and treatment. The investigation of novel miRNA-disease associations, however, is currently costly and time consuming. Over the years, several computational models have been proposed to prioritize potential miRNA-disease associations, but with limited usability or predictive capability. In order to fill this gap, we introduce TSMDA, a novel machine-learning method that leverages target and symptom information and negative sample selection to predict miRNA-disease association. TSMDA significantly outperforms similar methods, achieving an area under the receiver operating characteristic (ROC) curve (AUC) of 0.989 and 0.982 under 5-fold cross-validation and blind test, respectively. We also demonstrate the capability of the method to uncover potential miRNA-disease associations in breast, prostate, and lung cancers, as case studies. We believe TSMDA will be an invaluable tool for the community to explore and prioritize potentially new miRNA-disease associations for further experimental characterization. The method was made available as a freely accessible and user-friendly web interface at http://biosig.unimelb.edu.au/tsmda/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.